Ruining Bio is a pharmaceutical startup founded in 2018 that focuses on clinical medical solutions. The company offers a range of innovative products and services including tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. With a team of professionals specializing in materials science, chemistry, biomedical engineering, and clinical medicine, Ruining Bio is well-equipped to deliver cutting-edge solutions to meet the evolving needs of the healthcare industry.
The startup recently secured a significant CNY100.00M Series B investment on 24 January 2024. This latest funding round was led by prominent investors including Qiming Venture Partners, Dingxin Capital, and Guosen Innovation Equity. This investment highlights the confidence that key players in the venture capital space have in Ruining Bio's potential for growth and disruption within the pharmaceutical sector.
Overall, Ruining Bio's ability to attract notable investors and its innovative approach to addressing critical medical challenges positions the company as a promising player in the industry. With its strong foundation and support from renowned investors, Ruining Bio is well-positioned to drive impactful advancements in clinical medical solutions and make a significant mark in the pharmaceutical landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | CNY100.00M | 4 |
|
24 Jan 2024 |
| Series A | CNY100.00M | 3 |
|
04 Jan 2022 |
No recent news or press coverage available for Ruining Bio.
We care about your data, and we'd love to use cookies make your experience better.